We are live on ! Find out more
IOBT

IO Biotech
IOBT

Delisted

IOBT was delisted on the 6th of April, 2026.

Back to rankings

19 hedge funds and large institutions have $76.9M invested in IO Biotech in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.62% less ownership

Funds ownership: 52.18% → 51.56% (-0.62%)

5% less funds holding

Funds holding: 20 → 19 (-1)

17% less capital invested

Capital invested by funds: $92.6M → $76.9M (-$15.7M)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
19
Holders Change
-1
Holders Change %
-5%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$176K
2
Jane Street
Jane Street
New York
+$94.4K
3
E
Ergoteles
New York
+$73.5K
4
Morgan Stanley
Morgan Stanley
New York
+$49.8K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$10.3K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$945K
2
CCM
CAAS Capital Management
New York
-$323K
3
Squarepoint
Squarepoint
New York
-$98K
4
Citadel Advisors
Citadel Advisors
Florida
-$86K
5
VF
Virtu Financial
New York
-$83K

IOBT Hedge Fund Activity: Q1 2022 in Review

19 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q1 2022, worth a combined $76.9M — down 17% from $92.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IOBT and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $176K. The largest seller was Vanguard Group, cutting an estimated $945K.

  • 19 institutional investors held IO Biotech (IOBT) as of Q1 2022, down from 20 in Q4 2021.
  • Funds reported $76.9M of IO Biotech stock for Q1 2022, down 17% quarter-over-quarter.
  • 4 funds opened new IO Biotech positions in Q1 2022 and 5 closed out, a net change of -1 holder.
  • The largest IO Biotech buyer in Q1 2022 was Susquehanna International Group, an estimated $176K added.
  • The largest IO Biotech seller in Q1 2022 was Vanguard Group, an estimated $945K sold.

Based on aggregated 13F filings for Q1 2022.